Posts | Comments

Global Biologics Consulting Services Market is expected to witness a healthy CAGR of >15%

Contact Us
Avez Shaikh
121/7E Avenue Franklin Roosevelt 1050 Brussels, Be
Brussels
Brussels 1050 
india
Phone:32 498868079
aves.s@meditechinsights.com

While small molecules are either made synthetically or purified from plants, biologics are medicines made from living cells. Although small molecules comprise >90% of drugs on the market, pharmaceutical and biotech companies are gradually shifting their focus to manufacturing and developing highly profitable biologics drugs.

Complex Nature of Biologics and its Increasing Demand drives the Growth of Biologics Consulting Services Market

Compared to small molecules, biologics are large, highly complex, heterogeneous molecules, more expensive, sensitive to external conditions, need to go through challenging manufacturing processes and have stringent regulatory requirements, thus requiring a greater level of expertise.

With the increasingly complex and rapidly evolving biopharma industry, companies are looking for consultancies that are able to provide significant regulatory leadership, product development consulting, and expertise in all stages from early-stage discovery to commercialization. Moreover, the increasing importance of new biologics drugs is seen over the last few years, with biologics contributing to 25% of new molecule approvals in the US in 2020. This further boosts the demand for biologics consulting.

Emerging Influx of Small Biotech Lacking Manufacturing/Development Expertise

With the increased demand for novel therapies, there is a rising influx of small biotech firms that usually lack in-house capabilities and expertise. These firms are largely reliant on biologics consulting companies for end-to-end services from the exploratory phase to commercial manufacturing. Nevertheless, big biopharma companies need to work in a complex and dynamic environment that requires strict attention to meeting new regulatory standards. They also approach consulting firms to help them to maintain a strong track record of quality, compliance, and regulatory expertise.

Growing Demand for Advanced Technologies Consulting Services

Advanced therapies, such as cell and gene therapies and personalized vaccines require specialized expertise throughout the development, manufacturing, and regulatory process. Newer vaccine technologies like viral vector and mRNA where demand exceeds supply and capabilities/technical expertise may not exist even in large biopharma. Moreover, the rapidly evolving regulatory landscape makes it crucial to have up-to-date knowledge and expertise to successfully develop a product and gain a centralized market authorization (MA) in Europe and/or a Biologic License Authorization (BLA) in the US. With the rapidly growing demand for advanced biologics therapies, there is a corresponding demand for biologics consulting services.

Regional Overview: Biologics Consulting Services Market

From a geographical perspective, North America has a major market share of the global biologics consulting services market. This is mainly attributed to the growing biopharmaceutical industry, favorable government policies supporting biologics innovation, the presence of biologics consulting firms, significant R&D spending in the US, strict FDA regulations, and a greater focus on advanced therapies.

Competitive Landscape Analysis: Biologics Consulting Services Market

The global biologics consulting services market is highly competitive and fragmented. Some of the top and promising players operating in this market are IQVIA, NNE, ProductLife Group, Clarkston Consulting, Fingerpaint, Azenta Life Sciences, Biologics Consulting Group, UDG Healthcare, ProPharma Group, APCER Life Sciences, Freyr Solutions, ADVANCED CELL & GENE THERAPY, LLC, Dark Horse Consulting, and eXmoor pharma concepts limited.

Get Customized Research Report on Biologics Consulting Services Market @ https://meditechinsights.com/biologics-consulting-services-market/

Leave a Reply